CU24599B1 - Compuestos derivados de naftiridinona, quinolinona y piridopiridazinona - Google Patents
Compuestos derivados de naftiridinona, quinolinona y piridopiridazinonaInfo
- Publication number
- CU24599B1 CU24599B1 CU2019000042A CU20190042A CU24599B1 CU 24599 B1 CU24599 B1 CU 24599B1 CU 2019000042 A CU2019000042 A CU 2019000042A CU 20190042 A CU20190042 A CU 20190042A CU 24599 B1 CU24599 B1 CU 24599B1
- Authority
- CU
- Cuba
- Prior art keywords
- sup
- pyridopyridazinone
- naphthyridinone
- quinolinone
- compounds derived
- Prior art date
Links
- DYHGFTMEUMYPOC-UHFFFAOYSA-N 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)pyrido[2,3-d]pyridazin-5-one Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C(=O)N(CC=3C=CN=CC=3)N=2)=C1 DYHGFTMEUMYPOC-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229930185107 quinolinone Natural products 0.000 title abstract 2
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>La presente invención proporciona un compuesto de naftiridinona, quinolinona y piridopiridazinona de fórmula II ó fórmula III; donde R<sup>1</sup>, R<sup>3</sup>-R<sup>6</sup>, X² y X³ son como se define en la presente descripción. Estos compuestos se emplean en el tratamiento de arritmias como bloqueadores del canal GIRK 1/14.</p> <p>ESPACIO PARA FÓRMULA</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410930P | 2016-10-21 | 2016-10-21 | |
| CN2016102928 | 2016-10-21 | ||
| US201662413292P | 2016-10-26 | 2016-10-26 | |
| PCT/IB2017/056515 WO2018073788A1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20190042A7 CU20190042A7 (es) | 2019-11-04 |
| CU24599B1 true CU24599B1 (es) | 2022-06-06 |
Family
ID=60409317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2019000042A CU24599B1 (es) | 2016-10-21 | 2017-10-19 | Compuestos derivados de naftiridinona, quinolinona y piridopiridazinona |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10266531B2 (es) |
| EP (2) | EP3529251B1 (es) |
| JP (1) | JP7030802B2 (es) |
| KR (1) | KR102540872B1 (es) |
| CN (1) | CN109843887B (es) |
| AU (2) | AU2017344489C1 (es) |
| CL (1) | CL2019001023A1 (es) |
| CO (1) | CO2019003894A2 (es) |
| CR (1) | CR20190201A (es) |
| CU (1) | CU24599B1 (es) |
| DO (1) | DOP2019000100A (es) |
| EC (1) | ECSP19026973A (es) |
| ES (1) | ES2934234T3 (es) |
| FI (1) | FI3529251T3 (es) |
| HR (1) | HRP20221516T1 (es) |
| HU (1) | HUE060882T2 (es) |
| IL (1) | IL266128B (es) |
| JO (1) | JOP20190086A1 (es) |
| LT (1) | LT3529251T (es) |
| MX (1) | MX390044B (es) |
| PE (1) | PE20190735A1 (es) |
| PH (1) | PH12019500849A1 (es) |
| PL (1) | PL3529251T3 (es) |
| PT (1) | PT3529251T (es) |
| RS (1) | RS63841B1 (es) |
| SA (1) | SA519401614B1 (es) |
| SG (1) | SG11201902529WA (es) |
| SI (1) | SI3529251T1 (es) |
| TW (1) | TWI759343B (es) |
| UY (1) | UY37445A (es) |
| WO (1) | WO2018073788A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| PL3814347T3 (pl) | 2018-06-27 | 2023-07-24 | Bristol-Myers Squibb Company | Związki naftyrydynonu użyteczne jako aktywatory komórek t |
| WO2022074567A1 (en) | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
| CN115677739B (zh) * | 2021-07-31 | 2025-09-30 | 华南理工大学 | 一种o,o-二氟化硼配合物的制备方法 |
| AR127698A1 (es) * | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024061371A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州威诺森医药科技有限公司 | 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用 |
| WO2024241229A1 (en) * | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
| JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
| JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
| JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
| US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| EP0512042B1 (en) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| DE69531305T2 (de) | 1994-10-20 | 2004-05-13 | Wakunaga Seiyaku K.K. | Pyridoncarboxylat- derivate oder salze davon und antibakterielle zusammensetzungen die diese als aktiven bestandteil enthalten |
| EP0897919B1 (en) | 1996-04-19 | 2004-06-16 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| CA2271136C (en) | 1996-11-28 | 2008-11-25 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient |
| EP1086085A1 (en) | 1998-06-12 | 2001-03-28 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
| JP2002522388A (ja) | 1998-08-03 | 2002-07-23 | ビーエーエスエフ コーポレーション | 性機能障害の治療のためのピリジノン |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| WO2001076574A2 (en) | 2000-04-12 | 2001-10-18 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| JP2003040866A (ja) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤 |
| HUP0402310A2 (hu) | 2001-09-26 | 2005-02-28 | Bayer Pharmaceuticals Corporation | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| EP1513840B1 (en) | 2002-05-31 | 2006-10-04 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
| AU2003292039A1 (en) | 2002-11-18 | 2004-06-15 | Novartis Ag | Imidazo(1, 5a)pyridine derivatives and methods for treating aldosterone mediated diseases |
| EP1670795A1 (en) | 2003-09-18 | 2006-06-21 | ALTANA Pharma AG | Pharmacologically active imidazo 4,5-c pyridines |
| JP4719681B2 (ja) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | キナゾリンカリウムチャネル阻害剤 |
| ATE402180T1 (de) | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| EP2261225A1 (en) | 2004-05-28 | 2010-12-15 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| TW200608978A (en) | 2004-05-28 | 2006-03-16 | Speedel Experimenta Ag | Organic compounds |
| US8680079B2 (en) | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
| NZ587549A (en) | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| EP1910307A1 (en) | 2005-06-27 | 2008-04-16 | Exelixis, Inc. | Pyrazole based lxr modulators |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
| AU2006318212C1 (en) | 2005-11-23 | 2012-08-30 | The Board Of Regents Of The University Of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
| AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| WO2007116908A1 (ja) | 2006-04-04 | 2007-10-18 | Taiyo Nippon Sanso Corporation | メタン分離方法、メタン分離装置及びメタン利用システム |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| US20090264420A1 (en) | 2006-08-25 | 2009-10-22 | Gary Michael Ksander | Organic compounds |
| KR20090090395A (ko) | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| US8436035B2 (en) | 2006-12-18 | 2013-05-07 | Novartis Ag | Organic compounds |
| EP2094669A2 (en) | 2006-12-18 | 2009-09-02 | Novartis AG | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| RU2009139811A (ru) | 2007-03-29 | 2011-05-10 | Новартис АГ (CH) | Гетероциклические спиросоединения |
| EP2254873B1 (en) | 2008-02-22 | 2014-06-04 | Otsuka Pharmaceutical Co., Ltd. | Benzodiazepine compound and pharmaceutical composition |
| WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
| JP5954789B2 (ja) | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
| ES2573148T3 (es) | 2010-08-25 | 2016-06-06 | Neopharm Co., Ltd. | Compuestos y composición de 1H-benzo[d]imidazol-5-ilo para el tratamiento de enfermedades inflamatorias |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| WO2013007676A1 (en) | 2011-07-12 | 2013-01-17 | F. Hoffmann-La Roche Ag | Aminomethyl quinolone compounds |
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US9315499B2 (en) | 2012-04-05 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Cytomegalovirus inhibitor compounds |
| US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014152317A2 (en) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
| AR096022A1 (es) | 2013-04-11 | 2015-12-02 | Basf Se | Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales |
| WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
| US20160326165A1 (en) | 2013-12-26 | 2016-11-10 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| EP3307741B1 (de) * | 2015-06-09 | 2020-10-28 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/ar unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/es not_active Application Discontinuation
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/fi active
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/hr unknown
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/zh active Active
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en not_active Ceased
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 MX MX2019004484A patent/MX390044B/es unknown
- 2017-10-19 ES ES17801105T patent/ES2934234T3/es active Active
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/ko active Active
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/lt unknown
- 2017-10-19 CU CU2019000042A patent/CU24599B1/es unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/pl unknown
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/ja active Active
- 2017-10-19 TW TW106135836A patent/TWI759343B/zh active
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 SI SI201731279T patent/SI3529251T1/sl unknown
- 2017-10-19 RS RS20221152A patent/RS63841B1/sr unknown
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/hu unknown
- 2017-10-19 PT PT178011052T patent/PT3529251T/pt unknown
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/es unknown
- 2017-10-19 CR CR20190201A patent/CR20190201A/es unknown
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/es unknown
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/es unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/es unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/es unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/ar unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24599B1 (es) | Compuestos derivados de naftiridinona, quinolinona y piridopiridazinona | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| PH12018500457A1 (en) | New phenoxymethyl derivatives | |
| UY37302A (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| JOP20190166A1 (ar) | استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CL2017002097A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| ZA201700737B (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| CO2017007635A2 (es) | Nuevos compuestos bicíclicos | |
| EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| MX372962B (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
| CL2017001181A1 (es) | Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4) | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| MX386616B (es) | Compuestos de carfilzomib pegilados. | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201992302A1 (ru) | Соединения, используемые в качестве ингибиторов alcat1 | |
| EA201790613A1 (ru) | Триазольные соединения в качестве блокаторов кальциевых каналов т-типа | |
| MX379401B (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo | |
| EA201892341A1 (ru) | Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение |